MX354409B - Derivados de estradiol sustituidos en 6 para uso en remielinización de axones nerviosos. - Google Patents
Derivados de estradiol sustituidos en 6 para uso en remielinización de axones nerviosos.Info
- Publication number
- MX354409B MX354409B MX2013010650A MX2013010650A MX354409B MX 354409 B MX354409 B MX 354409B MX 2013010650 A MX2013010650 A MX 2013010650A MX 2013010650 A MX2013010650 A MX 2013010650A MX 354409 B MX354409 B MX 354409B
- Authority
- MX
- Mexico
- Prior art keywords
- remyelination
- nerve axons
- estradiol derivatives
- substituted estradiol
- substituted
- Prior art date
Links
- 210000003050 axon Anatomy 0.000 title abstract 2
- 150000002159 estradiols Chemical class 0.000 title abstract 2
- 210000005036 nerve Anatomy 0.000 title 1
- 208000016192 Demyelinating disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161454873P | 2011-03-21 | 2011-03-21 | |
| PCT/US2012/029973 WO2012129324A2 (en) | 2011-03-21 | 2012-03-21 | 6-substituted estradiol derivatives for use in remyelination of nerve axons |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013010650A MX2013010650A (es) | 2013-10-07 |
| MX354409B true MX354409B (es) | 2018-03-05 |
Family
ID=46877849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013010650A MX354409B (es) | 2011-03-21 | 2012-03-21 | Derivados de estradiol sustituidos en 6 para uso en remielinización de axones nerviosos. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9364486B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2688570B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6174563B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102080151B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN103501790B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2012230974B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112013024168A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2830515C (cg-RX-API-DMAC7.html) |
| DK (1) | DK2688570T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2561536T3 (cg-RX-API-DMAC7.html) |
| MX (1) | MX354409B (cg-RX-API-DMAC7.html) |
| SG (1) | SG193380A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012129324A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012129324A2 (en) * | 2011-03-21 | 2012-09-27 | Endece Llc | 6-substituted estradiol derivatives for use in remyelination of nerve axons |
| WO2014064712A2 (en) * | 2012-10-22 | 2014-05-01 | Intas Pharmaceuticals Limited | An improved process for the preparation of fulvestrant |
| JP2017512769A (ja) * | 2014-03-19 | 2017-05-25 | エンディース エルエルシーＥｎｄｅｃｅ，Ｌｌｃ | アルツハイマー病の治療のための６−置換エストラジオール誘導体 |
| US20210024568A1 (en) * | 2019-07-23 | 2021-01-28 | Endece Llc | Methods for modulation of lipoprotein lipase and apolipoprotein c2 expression and/or activity in the treatment of peripheral and central nervous system tissue disease states |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4136160A (en) * | 1977-08-17 | 1979-01-23 | Cohen Steven R | Specific assay for active demyelinization |
| JPH0193529A (ja) * | 1987-10-05 | 1989-04-12 | Mect Corp | シアロシルコレステロールの脱髄性疾患治療剤 |
| JPH01193529A (ja) | 1988-01-27 | 1989-08-03 | Yoshitsugu Takano | 液体循環装置 |
| US8168621B2 (en) * | 2005-09-30 | 2012-05-01 | Endece, Llc | 6-substituted estradiol derivatives and methods of use |
| JP5255444B2 (ja) * | 2005-09-30 | 2013-08-07 | エンディース エルエルシー | （ｓ）−６−メチルオキサアルキルエキセメスタン化合物および関連する使用方法 |
| US10174070B2 (en) | 2005-09-30 | 2019-01-08 | Endece Llc | 6-substituted estradiol derivatives and methods of use |
| KR101499266B1 (ko) * | 2006-11-30 | 2015-03-05 | 엔디씨, 엘엘씨 | 6-알콕시알킬 에스트라디올 유도체 및 사용법 |
| AU2011302065B2 (en) | 2010-09-14 | 2016-12-01 | Endece, Llc | 6-substituted demethyl-estradiol derivatives as ER-beta agonists |
| WO2012129324A2 (en) * | 2011-03-21 | 2012-09-27 | Endece Llc | 6-substituted estradiol derivatives for use in remyelination of nerve axons |
-
2012
- 2012-03-21 WO PCT/US2012/029973 patent/WO2012129324A2/en not_active Ceased
- 2012-03-21 ES ES12761491.5T patent/ES2561536T3/es active Active
- 2012-03-21 CN CN201280014512.2A patent/CN103501790B/zh not_active Expired - Fee Related
- 2012-03-21 DK DK12761491.5T patent/DK2688570T3/en active
- 2012-03-21 EP EP12761491.5A patent/EP2688570B1/en not_active Not-in-force
- 2012-03-21 CA CA2830515A patent/CA2830515C/en not_active Expired - Fee Related
- 2012-03-21 AU AU2012230974A patent/AU2012230974B2/en not_active Ceased
- 2012-03-21 MX MX2013010650A patent/MX354409B/es active IP Right Grant
- 2012-03-21 SG SG2013067962A patent/SG193380A1/en unknown
- 2012-03-21 JP JP2014501213A patent/JP6174563B2/ja not_active Expired - Fee Related
- 2012-03-21 KR KR1020137027657A patent/KR102080151B1/ko not_active Expired - Fee Related
- 2012-03-21 CN CN201610455383.0A patent/CN106420767A/zh active Pending
- 2012-03-21 BR BR112013024168A patent/BR112013024168A2/pt not_active IP Right Cessation
- 2012-03-21 US US13/426,364 patent/US9364486B2/en active Active
-
2016
- 2016-06-10 US US15/179,349 patent/US9636348B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2012230974A1 (en) | 2013-09-26 |
| US9636348B2 (en) | 2017-05-02 |
| CA2830515C (en) | 2015-09-15 |
| EP2688570A4 (en) | 2014-09-10 |
| BR112013024168A2 (pt) | 2017-07-11 |
| CN103501790A (zh) | 2014-01-08 |
| EP2688570B1 (en) | 2015-11-18 |
| KR102080151B1 (ko) | 2020-02-21 |
| CA2830515A1 (en) | 2012-09-27 |
| US20120245131A1 (en) | 2012-09-27 |
| JP6174563B2 (ja) | 2017-08-02 |
| EP2688570A2 (en) | 2014-01-29 |
| KR20140074253A (ko) | 2014-06-17 |
| AU2012230974B2 (en) | 2016-05-12 |
| SG193380A1 (en) | 2013-10-30 |
| CN106420767A (zh) | 2017-02-22 |
| WO2012129324A2 (en) | 2012-09-27 |
| ES2561536T3 (es) | 2016-02-26 |
| US20160279144A1 (en) | 2016-09-29 |
| CN103501790B (zh) | 2016-08-17 |
| MX2013010650A (es) | 2013-10-07 |
| WO2012129324A9 (en) | 2012-11-15 |
| US9364486B2 (en) | 2016-06-14 |
| DK2688570T3 (en) | 2015-12-21 |
| JP2014508807A (ja) | 2014-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA030383B9 (ru) | Бициклически замещённые урацилы, способы их получения, их применение, лекарственное средство и способ лечения с их применением | |
| PH12014500460A1 (en) | Substituted annellated pyrimidine and the use thereof | |
| MX2015005286A (es) | Procedimiento para la preparación de derivados del ácido biliar. | |
| PH12014501258A1 (en) | Pyrazolopyridine derivatives, preparation process therefor and therapeutic use thereof | |
| TN2014000122A1 (en) | 1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases | |
| PH12015502839A1 (en) | Antiviral compounds | |
| NZ705705A (en) | Ret inhibitor | |
| WO2011123946A8 (en) | Kinase inhibitors and method of treating cancer with same | |
| MX2020005533A (es) | Nuevo proceso para la preparacion de derivados de piperidinilo-azetidina e intermediarios de los mismos, en donde dichos compuestos son inhibidores de mek. | |
| EP2750694B8 (en) | Methods and compositions relating to p62 for the treatment and prophylaxis of cancer | |
| MY184858A (en) | Substituted pyridopyrimidine compounds and their use as flt3 inhibitors | |
| NZ711343A (en) | Sodium salt of (2s, 5r)-6-benzyloxy-7-oxo-1,6-diaza-bicyclo [3.2.1 ] octane-2-carboxylic acid and its preparation | |
| MX2014002936A (es) | Nuevos derivados de acido betulinico con actividad antiviral. | |
| MX2014005726A (es) | Metodo de tratamiento de una enfermedad proliferativa. | |
| BR112014014762A8 (pt) | método para preparação de cisteína ou de um derivado desta usando uma nova o-fosferina sulfidrilase | |
| IN2014MN01469A (cg-RX-API-DMAC7.html) | ||
| MX354409B (es) | Derivados de estradiol sustituidos en 6 para uso en remielinización de axones nerviosos. | |
| EP2663326A1 (en) | Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries | |
| GB201107985D0 (en) | Process | |
| MX2013006658A (es) | Métodos para producir y usar brasinoesteroides para promover el crecimiento, la reparación y mantenimiento del músculo esquelético y la piel. | |
| MX348841B (es) | Derivados de pirimidooxazocina como inhibidores de mtor. | |
| IN2014DN10658A (cg-RX-API-DMAC7.html) | ||
| MX2015002705A (es) | Compuestos de piridinona para usarse en terapia fotodinamica. | |
| IN2014DN07498A (cg-RX-API-DMAC7.html) | ||
| UA71930U (ru) | Способ повышения эффективности вакцинации против гриппа у часто болеющих детей |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |